• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Milrinone and dobutamine show no difference for cardiogenic shock treatment

byHarsh Shah
August 17, 2021
in Cardiology, Emergency, Neurology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Milrinone was shown not to be significantly different than dobutamine for the treatment of cardiogenic shock.

2. In-hospital deaths of patients treated with either milrinone or dobutamine were not significantly different.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Cardiogenic shock is a state of low cardiac output causing end-organ hypoperfusion. Treatments have aimed to improve hemodynamic measures with various medications and devices. Milrinone, a phosphodiesterase 2 inhibitor, is known to increase cardiac inotropy, lusitropy, and peripheral vasodilation. On the other hand, dobutamine, a synthetic catecholamine, improves blood pressure by increasing cardiac output. As such, this study compared the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. The study determined milrinone and dobutamine were not significantly different in the treatment of cardiogenic shock. Furthermore, there was no significant difference for in-hospital deaths, resuscitated cardiac arrest, and receipt of mechanical circulatory support. The randomized control trial was limited by dose adjustments based on individual physician assessment rather than a standard protocol and patient recruitment was from a single center. Nonetheless, this study’s results are significant, and its findings highlight no difference in patient outcomes after using milrinone or dobutamine for cardiogenic shock.

Click to read the study in NEJM

Relevant Reading: Efficacy of milrinone and dobutamine in low cardiac output states: systematic review and meta-analysis

In-Depth [randomized controlled trial]: This randomized control trial study enrolled 192 participants at a single cardiac care institute in Canada. Participants included in the study were at least 18 years of age, admitted to the cardiac intensive care unit, and were diagnosed with cardiogenic shock as defined by the Society for Cardiovascular Angiography and Interventions. Participants with a stage A cardiogenic shock were excluded from this study. The participants were randomized in a 1:1 ratio to receive milrinone or dobutamine therapy, respectively. The primary outcome was a composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy. The primary outcome occurred in 47 participants of the milrinone group (47%) compared to 52 participants in the dobutamine group (54%) (relative risk [RR], 0.90; 95% confidence interval [CI], 0.69 to 1.19; P = 0.47). Furthermore, a time-to-event analysis showed no significant difference between the two treatment groups (hazard ratio [HR], 0.91; 95% CI, 0.61 to 1.34). Additionally, in-hospital death from any causes occurred in 35 participants of the milrinone group (37%) compared to 41 participants in the dobutamine group (43%) (RR, 0.85; 95% CI, 0.60 to 1.21). There was no significant difference in resuscitated cardiac arrest between both groups (HR, 0.78; 95% CI, 0.29 to 2.07) and receipt of mechanical support (HR, 0.78; 95% CI, 0.36 to 1.71). Taken together, milrinone and dobutamine treatment were shown to have no significant difference in the treatment of cardiogenic shock.

RELATED REPORTS

Higher protein doses do not improve outcomes in mechanically ventilated patients with high nutritional risk

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

Oxygenation targets do not alter outcomes in critically ill patients

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: cardiogenic shockdobutaminein-hospital deathmechanical ventilationmilrinone
Previous Post

Pain and sleep may have a bidirectional causal relationship

Next Post

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

RelatedReports

Chronic Disease

Higher protein doses do not improve outcomes in mechanically ventilated patients with high nutritional risk

February 28, 2023
#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival
StudyGraphics

#VisualAbstract: Early mobilization after ICU mechanical ventilation does not improve survival

December 1, 2022
Chronic Disease

Oxygenation targets do not alter outcomes in critically ill patients

November 14, 2022
Propofol appears safe and effective in procedural sedation for cardioversion
Cardiology

Contemporary pattern of treatment time and in-hospital mortality among US patients with ST-segment elevation myocardial infarction between 2018-2021

November 9, 2022
Next Post
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

Higher blood pressure targets in sepsis did not reduce mortality

Breastfeeding not associated with late-onset group B Streptococcus disease in infants

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options